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Optical control of mammalian endogenous transcription and epigenetic states 
 
Abstract 
The dynamic nature of gene expression enables cellular programming, 
homeostasis and environmental adaptation in living systems. Dissection of causal gene 
functions in cellular and organismal processes therefore necessitates approaches that 
enable spatially and temporally precise modulation of gene expression. Recently, a 
variety of microbial and plant-derived light-sensitive proteins have been engineered as 
optogenetic actuators, enabling high-precision spatiotemporal control of many cellular 
functions1-11. However, versatile and robust technologies that enable optical modulation 
of transcription in the mammalian endogenous genome remain elusive. Here we describe 
the development of light-inducible transcriptional effectors (LITEs), an optogenetic two-
hybrid system integrating the customizable TALE DNA-binding domain12-14 with the 
light-sensitive cryptochrome 2 protein and its interacting partner CIB1 from Arabidopsis 
thaliana. LITEs do not require additional exogenous chemical cofactors, are easily 
customized to target many endogenous genomic loci, and can be activated within minutes 
with reversibility6, 15. LITEs can be packaged into viral vectors and genetically targeted to 
probe specific cell populations. We have applied this system in primary mouse neurons, 
as well as in the brain of freely behaving mice in vivo to mediate reversible modulation of 
mammalian endogenous gene expression as well as targeted epigenetic chromatin 
modifications. We explore the modularity of the LITE approach through the development 
 iv 
of CRISPR/Cas9 transcriptional effectors in either constitutively active or light-inducible 
contexts. The LITE system establishes a novel mode of optogenetic control of 
endogenous cellular processes and enables direct testing of the causal roles of genetic and 
epigenetic regulation in normal biological processes and disease states. 
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Section I: Introduction 
 
The dynamic nature of gene expression enables cellular programming, 
homeostasis, and environmental adaptation in living systems. Internal and external 
cellular inputs are functionally integrated and processed by spatiotemporally precise 
regulation within transcriptional networks. These networks in turn orchestrate the 
interaction and organization of cells within tissues and whole organisms. Dissecting the 
contributions of genes to cellular and organismal function therefore requires an approach 
to enable spatially and temporally controlled modulation of gene expression. 
 
Light provides a fast, reversible, and spatially targeted modality for manipulating a 
variety of biological processes. Microbial- and plant-derived light-sensitive proteins have 
been engineered as optogenetic actuators, allowing precise optical control of cellular 
functions including membrane potential1, 2, 16, intracellular biochemical signaling17, 
protein interactions3-6, and heterologous gene expression4, 6-9, 18. However, the ability to 
directly modulate endogenous gene expression using light has remained elusive. 
 
An ideal optogenetic approach for controlling endogenous gene transcription would be 
easily generalizable to target any gene locus, would not require manipulation of the 
endogenous genomic sequence or the addition of exogenous co-factors, and would 
exhibit fast and reversible kinetics. The DNA-binding domain of transcription activator-
like effectors (TALEs)12, 13 from Xanthamonas sp. can be easily customized to bind a 
variety of DNA sequences in mammalian cells14, 19, 20. TALE DNA-binding domains are 
 2 
modular and can be fused with a variety of effector domains, including nucleases, 
transcriptional activators, and transcriptional repressors to edit or modulate endogenous 
mammalian genomic loci14, 19-21. We sought to combine TALEs with light-sensitive plant 
proteins to create a suite of tools for enabling spatiotemporally precise control of 
endogenous gene transcription. 
 
This work describes the development of Light-Inducible Transcriptional Effectors 
(LITEs), a two-component system integrating the customizable TALE DNA-binding 
domain with the light-sensitive cryptochrome 2 protein and its interacting partner CIB1 
from Arabidopsis thaliana6, 15. LITEs can be engineered to mediate positive and negative 
regulation of endogenous mammalian gene expression in a reversible manner, and 
changes in transcript levels occur within minutes after stimulation. Like other optogenetic 
tools, LITEs can be packaged into viral vectors and genetically targeted to specific cell 
types to probe gene function within specific cell populations. We demonstrate the 
application of this system in primary neurons as well as in the mouse brain in vivo. We 
explore the modularity of LITEs by modifying the system to enable RNA targeted 
transcriptional modulation via the RNA-guided CRISPR/Cas9 system22, 23. Finally, we 
engineer new approaches to Cas9-based activation, in an effort to improve the efficiency 
and ease of endogenous transcriptional modulation. 
 
Section II: Engineering light-inducible transcriptional effectors 
 
The LITE system employs a modular design consisting of two independent 
components (Fig. 1a): The first component is the genomic anchor and includes a 
customizable DNA-binding domain, based on transcription activator-like effectors 
(TALEs)12, 13 from Xanthamonas sp., fused to the light-sensitive cryptochrome 2 (CRY2) 
protein from Arabidopsis thaliana6, 15 (TALE-CRY2). The second component includes 
the CRY2 interacting partner CIB16, 15 fused to a desired effector domain (CIB1-
effector). In the absence of light (inactive state), TALE-CRY2 binds the promoter region 
of the target gene while CIB1-effector remains free within the nuclear compartment. 
Illumination with blue light (peak ~450 nm) triggers a conformational change in CRY2 
and subsequently recruits CIB1-effector (VP64 shown in Fig. 1a) to the target locus to 
mediate transcriptional modulation. This modular design allows each LITE component to 
be independently engineered, allowing the same genomic anchor to be combined with 
activating or repressing effectors21, 24 to exert positive and negative transcriptional control 
over the same endogenous genomic locus. In principle, the genomic anchor may also be 
replaced with other DNA binding domains such as zinc finger proteins24 or RNA-guided 
DNA binding domains based on nucleolytically inactive mutants of Cas922, 25-28 (Section 
VI). 
 
In order to identify the most effective architecture, we assessed the efficacy of different 
LITE designs by measuring blue light illumination induced transcriptional changes of the 
neural lineage-specifying transcription factor neurogenin 2 (Neurog2) (Fig. 1b). 3 out of 
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4 initial LITE pairings produced significant light-induced Neurog2 mRNA up-regulation 
in Neuro 2a cells (p < 0.001, Fig. 1b).  
 
Figure 1 | Design and optimization of the LITE system. a, Schematic of the LITE system. 
Light stimulation induces dimerization of CRY2 and CIB1, recruiting the effector to the target 
promoter. b, LITE architecture was optimized by fusing TALE and the transcriptional activator 
VP6414, 24 to different truncations of CRY2 and CIB16 (n next to each bar). c, Time-course of 
light-dependent Neurog2 upregulation and decay post-illumination (n = 4 biological replicates; 
*p  <  0.05; ***p  <  0.001). Cells were stimulated with 5  mW/cm2 light (466  nm, 1  s pulses at 
0.067  Hz). Mean  ±  s.e.m. in all panels. 
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Of the combinations tested, TALE(Neurog2)-CRY2PHR::CIB1-VP64 yielded the 
strongest light-mediated transcription activation as well as the highest induction ratio 
(light/no light mRNA levels). Therefore TALE-CRY2PHR::CIB1-VP64 was used in 
subsequent experiments. To ensure optimal function, we also systematically tuned light 
stimulation parameters and effector domains (wavelength, Fig. 2a; duty cycle, Fig. 2b; 
light intensity29, Fig. 2c and d; and choice of activation domain, Fig. 2e). 
 
Figure 2 | Engineering of light stimulation parameters and activation domains of LITEs. a, 
Illustration of the absorption spectrum of CRY2 in vitro. Cryptochrome 2 was optimally activated 
by 350–475  nm light29. A sharp drop in absorption and activation was seen for wavelengths 
greater than 480  nm. Spectrum was adapted from Banerjee et al29. b, Impact of illumination duty 
cycle on LITE-mediated gene expression. Varying duty cycles (illumination as percentage of total 
time) were used to stimulate 293FT cells expressing LITEs targeting the KLF4 gene. KLF4 
expression levels were compared to cells expressing GFP only. Stimulation parameters were: 
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466  nm, 5  mW/cm2 for 24  h. Pulses were performed at 0.067  Hz with the following durations: 
1.7% = 0.25  s pulse, 7% = 1  s pulse, 27% = 4  s pulse, 100% = constant illumination. 
(mean  ±  s.e.m.; n = 3–4 biological replicates.) c, The transcriptional activity of CRY2PHR/ CIB1 
LITE was found to vary according to the intensity of 466  nm blue light. Neuro 2a cells were 
stimulated for 12  h at a 7% duty cycle (1  s pulses at 0.067  Hz). All Neurog2 mRNA levels were 
measured relative to cells expressing GFP only (mean  ±  s.e.m.; n = 3–4 biological replicates). d, 
Light-induced toxicity measured as the percentage of cells positive for red fluorescent ethidium 
homodimer-1 versus calcein-positive cells (mean  ±  s.e.m.; n = 3 biological replicates; **p  <  0.01). 
e, We compared the activation domains VP16 and p65 in addition to VP64 to test the modularity 
of the LITE CIB1–effector component. Neuro 2a cells transfected with LITE were stimulated for 
24  h with 466  nm light at an intensity of 5mW/cm2 and a duty cycle of 7% (1  s pulses at 
0.067  Hz). All three domains produced a significant light-dependent Neurog2 mRNA 
upregulation (p  <  0.001). We selected VP64 for subsequent experiments due to its lower basal 
activity in the absence of light-stimulation (mean  ±  s.e.m.; n = 3–4 biological replicates).
 
Although the interaction between CRY2 and CIB1 occurs on a sub-second timescale6, 
LITE-mediated transcriptional activation is likely dependent on many factors, including 
rate of transcription, mRNA processing, and transcript stability30, 31. We found that LITE-
mediated Neurog2 expression increased considerably as early as 30 min after initial 
stimulation and rose steadily until saturating at 12 h with approximately 20-fold up-
regulation compared to GFP-transfected negative controls (Fig. 1c). Interestingly, 
Neurog2 transcript levels continued to increase for up to 30 min post-illumination, an 
effect that may have resulted from residual CRY2PHR-CIB1 dimerization or from 
previously recruited RNA polymerases. Thereafter, Neurog2 mRNA returned to baseline 
levels with a half-life of ~3 h. In contrast, a small-molecule inducible TALE system 
based on the plant hormone abcisic acid receptor32 exhibited slower activation kinetics 
(Fig. 3). 
Figure 2 (Continued) 
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Figure 3 | Chemical induction of endogenous gene transcription. a, Schematic showing the 
design of a chemically inducible two-hybrid TALE system based on the abscisic acid (ABA) 
receptor system. ABI and PYL dimerize upon the addition of ABA and dissociate when ABA is 
withdrawn. b, Time-course of ABA-dependent Neurog2 upregulation. 250  µM of ABA was 
added to Neuro 2a cells expressing TALE(Neurog2)–ABI and PYL–VP64. Fold mRNA increase 
was measured at the indicated time points after the addition of ABA. c, Decrease of Neurog2 
mRNA levels after 24  h of ABA stimulation. All Neurog2 mRNA levels were measured relative 
to GFP-expressing control cells (mean  ±  s.e.m.; n = 3–4 biological replicates).
Section III: TALEs and LITEs in the mammalian brain 
 
To apply LITE for neuronal applications, we developed a simplified process for 
adeno-associated virus (AAV) production (Fig. 4) and an AAV-based vector (Fig. 5a and 
b) for the delivery of TALE genes. The ssDNA-based genome of AAV is less susceptible 
to recombination, providing an advantage over lentiviral vectors33. We evaluated a panel 
of 28 TALE activators targeting the mouse genome in primary neurons and found that 
most were able to up-regulate transcription in primary neurons (Fig. 5c). Moreover, in 
vivo expression of TALE(Grm2)-VP64 in the prefrontal cortex (PFC) (Fig. 5d and e) 
induced a 2.5-fold increase in Grm2 mRNA levels compared to GFP-only controls (Fig. 
5f). 
 
Figure 4 | Efficient AAV production using cell supernatant. a, Lentiviral and AAV vectors 
carrying GFP were used to test transduction efficiency. b, Primary cortical neurons were 
transduced with supernatant derived from the same number of lentivirus- or AAV-transduced 
293FT cells. Representative images of GFP expression were collected at 7  days post infection. 
Scale bars, 50  µm. c, The depicted process was developed for the production of AAV supernatant 
and subsequent transduction of primary neurons. 293FT cells were transfected with an AAV 
vector carrying the gene of interest, the AAV1 serotype packaging vector (pAAV1), and helper 
plasmid (pDF6) using PEI. 48  h later, the supernatant was collected and filtered through a 
0.45 µm PVDF membrane. Primary neurons were then transduced with supernatant and 
remaining aliquots were stored at −80  °C. Stable levels of AAV construct expression were 
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reached after 5–6  days. AAV supernatant production following this process can be used for 
production of up to 96 different viral constructs in 96-well format. 
 
 
Figure 5 | In vitro and in vivo AAV-mediated TALE delivery targeting endogenous loci in 
neurons. a, Schematic of AAV vectors for TALE delivery. b, Representative images of primary 
cortical neurons expressing TALE–VP64. c, TALE–VP64 constructs targeting a variety of 
endogenous genes were screened for transcriptional activation in primary cortical neurons 
(*p  <  0.05; **p  <  0.01; ***p  <  0.001; n = 3 biological replicates). d, TALE–VP64 expression in 
PFC. DAPI, 4′,6-diamidino-2-phenylindole; Cg1, cingulate cortex area 1; PLC, prelimbic cortex; 
ILC, infralimbic cortex. e, Higher magnification image of TALE–VP64 expressing neurons in 
Figure 4 (Continued) 
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PFC. f, Grm2 mRNA upregulation by TALE–VP64 in vivo in PFC (n = 4 animals). Mean  ±  s.e.m. 
in all panels. 
 
Similarly, we introduced LITEs into primary cortical neurons via co-delivery of two 
AAVs (Fig. 6a and b). We tested a Grm2-targeted LITE at 2 light pulsing frequencies 
with a reduced duty cycle of 0.8% to ensure neuron health (Fig. 7). Both stimulation 
conditions achieved a ~7-fold light-dependent increase in Grm2 mRNA levels (Fig. 6c). 
Further study verified that substantial target gene expression increases could be attained 
quickly (4-fold up-regulation of mRNA within 4 h; Fig. 6d). In addition, we observed 
significant up-regulation of mGluR2 protein after stimulation, confirming that LITE-
mediated transcriptional changes are translated to the protein level (p < 0.01 vs GFP 
control, p < 0.05 vs no-light condition; Fig. 6e).  
 
Figure 6 | LITE-mediated optogenetic modulation of endogenous transcription in primary 
neurons. a, Schematic of AAV LITE constructs. b, Images of primary neurons expressing LITE 
Figure 5 (Continued) 
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constructs. HA, haemagglutinin tag. c, Light-induced activation of Grm2 in primary neurons after 
24  h of stimulation (250  ms pulses at 0.033  Hz or 500  ms pulses at 0.016  Hz; 5  mW/cm2 ; n = 4 
biological replicates). d, Upregulation of Grm2 in primary cortical neurons after 4  h or 24  h of 
stimulation. Expression levels are shown relative to neurons transduced with GFP only (n=3-4 




Figure 7 | Impact of light duty cycle on primary neuron health. The effect of light stimulation 
on primary cortical neuron health was compared for duty cycles of 7%, 0.8%, and no light 
conditions. Calcein was used to evaluate neuron viability. Brightfield images show cell 
morphology and integrity. Primary cortical neurons were stimulated with the indicated duty cycle 
for 24  h with 5  mW/cm2 of 466  nm light. Representative images, scale bar, 50  µm. Pulses were 
performed in the following manner: 7% duty cycle = 1  s pulse at 0.067  Hz, 0.8% duty cycle = 
0.5  s pulse at 0.0167  Hz. 
 
To test the in vivo functionality of the LITE system, we stereotactically delivered a 1:1 
mixture of high titer AAV vectors carrying TALE(Grm2)-CIB1 and CRY2PHR-VP64 
into the PFC. We used a previously established fiber optic cannula system34 to deliver 
light to LITE-expressing neurons in vivo (Fig. 8). After 12 h of stimulation, we observed 
a significant increase in Grm2 mRNA compared with unstimulated PFC (Fig. 8d, p ≤ 
Figure 6 (Continued) 
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0.01). Taken together, these results confirm that LITEs enable optical control of 
endogenous gene expression in cultured neurons and in vivo.  
 
Figure 8 | LITE-mediated optogenetic modulation of endogenous transcription in vivo. a, 
Schematic of in vivo optogenetic stimulation setup. b, Representative images of PFC neurons 
expressing both LITE components. c, Co-transduction efficiency of LITE components by 
AAV1/2 in vivo in mouse infralimbic cortex. Cells transduced by TALE(Grm2)–CIB1 alone, 
CRY2PHR–VP64 alone, or co-transduced were calculated as a percentage of all transduced cells 
(mean  ±  s.e.m.; n = 9 fields from 3 animals). d, Light-induced activation of endogenous 
Grm2 expression using LITEs transduced into ILC. (**p  <  0.01; n = 4–6 animals.)
Section IV: Inducible nuclear import and other approaches to LITE optimizations 
 
Having observed persistent baseline up-regulation in vivo, we undertook further 
rounds of optimization to reduce background activity and improve the gene induction 
ratio of LITEs. We observed that TALE(Grm2)-CIB1 alone produced similar levels of 
up-regulation as background activation, yet CRY2PHR-VP64 alone did not significantly 
affect transcription (Fig. 9). Therefore we rationalized that LITE-dependent background 
transcriptional activation arises mainly from TALE-CIB1. 
 
Figure 9 | Basal activation by LITE components in primary neurons.  Grm2 mRNA levels 
were determined in primary neurons transfected with individual LITE components. Primary 
neurons expressing TALE(Grm2)–CIB1 alone led to a similar increase in Grm2 mRNA levels as 
unstimulated cells expressing the complete LITE system (mean  ±  s.e.m.; n = 3–4 biological 
replicates). 
 
The subsequent comprehensive screen to reduce baseline TALE-CIB1-mediated up-
regulation focuses on two strategies: First, although CIB1 is a plant transcription factor, it 
may have intrinsic activity in mammalian cells35. To address this, we deleted three CIB1 
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regions conserved amongst basic helix-loop-helix transcription factors of higher plants 
(Fig. 10). Second, to prevent TALE-CIB1 from binding the target locus in absence of 
light, we engineered TALE-CIB1 to localize in the cytoplasm pending light-induced 
dimerization with the NLS-containing CRY2PHR-VP64 (Fig. 11). To test both strategies 
independently or in combination, we evaluated 73 distinct LITE architectures and 
identified 12 effector/targeting-domain pairs (denoted by the “+” column in Fig. 10) with 
both improved light-induction efficiency and reduced background (fold mRNA increase 
in the no-light condition compared with the original LITE; p < 0.05).  
 
Figure 10 | Effects of LITE component engineering on activation, background signal and 
fold induction. Protein modifications were used to find LITE components resulting in reduced 
background transcriptional activation while improving induction ratio by light. In brief, nuclear 
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localization signals and mutations in an endogenous nuclear export signal were used to improve 
nuclear import of the CRY2PHR–VP64 component. Several variations of CIB1 intended to either 
reduce nuclear localization or CIB1 transcriptional activation were pursued to reduce the 
contribution of the TALE–CIB1 component to background activity. The results of all tested 
combinations of CRY2PHR–VP64 and TALE–CIB1 are shown. The table to the left of the bar 
graphs indicates the particular combination of domains/mutations used for each condition. Each 
row of the table and bar graphs contains the component details, light/no light activity, and 
induction ratio by light for the particular CRY2PHR/CIB1 combination. Combinations that 
resulted in both decreased background and increased fold induction compared to LITE1.0 are 




Figure 11 | Inducible nuclear import.  a, In the absence of light, the TALE–CIB1 LITE 
component resides in the cytoplasm due to the absence of a nuclear localization signal, NLS (or 
the addition of a nuclear export signal, NES). The CRY2PHR–VP64 component containing an 
NLS on the other hand is actively imported into the nucleus on its own. b, In the presence of blue 
light, TALE–CIB1 binds to CRY2PHR. The NLS present in CRY2PHR–VP64 then mediates 
nuclear import of the complex comprising both LITE components, enabling them to activate 
transcription at the targeted locus. 
 
One architecture successfully incorporating both strategies, designated LITE2.0, 
demonstrated the strongest light induction (light/no-light = 20.4) and resulted in greater 
than 6-fold reduction of background activation compared with the original design (Fig. 
Figure 10 (Continued) 
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12a). Another architecture, LITE1.9.1, produced minimal background activation (1.06) 
while maintaining four-fold light induction (Fig. 12b).  
 
Figure 12 | LITE2.0 and selected LITE1.9 optimizations. a, LITE2.0 significantly reduces the 
level of background activation in Neuro 2a cells (n = 3 biological replicates). Mean  ±  s.e.m. in all 
panels. b, Several CRY2PHR–VP64/TALE–CIB1 combinations from the engineered LITE 
component screen were of particular note. LITE1.9.0, which combined the α-importin NLS 
effector construct with a mutated endogenous NLS and Δ276–307 TALE–CIB1 construct, 
exhibited an induction ratio greater than 9 and an absolute light activation of more than 180. 
LITE1.9.1, which combined the unmodified CRY2PHR–VP64 with a mutated NLS, Δ318–334, 
AD5 NES TALE–CIB1 construct, achieved an induction ratio of 4 with a background activation 
of 1.06. A selection of other LITE1.9 combinations with background activations lower than 2 and 
induction ratios ranging from 7 to 12 were also highlighted (mean  ±  s.e.m.; n = 2–3 biological 
replicates). 
 
Modification strategies for background elimination 
CRY2PHR-VP64 Constructs: Three new constructs were designed with the goal of 
improving CRY2PHR-VP64 nuclear import. First, the mutations L70A and L74A within 
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a predicted endogenous nuclear export sequence of CRY2PHR were created to limit 
nuclear export of the protein (referred to as ‘*’ in the Effector column of Fig. 10). 
Second, the α-importin nuclear localization sequence was fused to the N-terminus of 
CRY2PHR-VP64 (referred to as ‘A’ in the Effector column of Fig. 10). Third, the SV40 
nuclear localization sequence was fused to the C-terminus of CRY2PHR-VP64 (referred 
to as ‘P’ in the Effector column of Fig. 10). 
 
TALE-CIB1 Linkers: The SV40 NLS linker between TALE and CIB1 used in LITE 1.0 
was replaced with one of several linkers designed to increase nuclear export of the 
TALE-CIB1 protein (The symbols used in the CIB1 Linker column of Fig. 10 are shown 
in parentheses): a flexible glycine-serine linker (G), an adenovirus type 5 E1B nuclear 
export sequence (W), an HIV nuclear export sequence (M), a MAPKK nuclear export 
sequence (K), and a PTK2 nuclear export sequence (P). 
 
NLS* Endogenous CIB1 Nuclear Localization Sequence Mutation: A nuclear 
localization signal exists within the wild type CIB1 sequence. This signal was mutated in 
NLS* constructs at K92A, R93A, K105A, and K106A in order to diminish TALE-CIB1 
nuclear localization (referred to as ‘N’ in the NLS* column of Fig. 10). 
 
ΔCIB1 Transcription Factor Homology Deletions: In an effort to eliminate possible 
basal CIB1 transcriptional activation, deletion constructs were designed in which regions 
of high homology to basic helix-loop-helix transcription factors in higher plants were 
removed. These deleted regions consisted of Δaa230-256, Δaa276-307, Δaa308-334 
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(referred to as ‘1’ ‘2’ and ‘3’ in the ΔCIB1 column of Fig. 10). In each case, the deleted 
region was replaced with a 3 residue GGS link. 
 
NES Insertions into CIB1:  One strategy to facilitate light-dependent nuclear import of 
TALE-CIB1 was to insert an NES in CIB1 at its dimerization interface with CRY2PHR 
such that the signal would be concealed upon binding with CRY2PHR. To this end, an 
NES was inserted at different positions within the known CRY2 interaction domain 
CIBN (aa 1-170). The positions are as follows (The symbols used in the NES column of 
Fig. 10 are shown in parentheses): aa28 (1), aa52 (2), aa73 (3), aa120 (4), aa140 (5), 
aa160 (6). 
 
*bHLH basic Helix-Loop-Helix Mutation: To reduce direct CIB1-DNA interactions, 
several basic residues of the basic helix-loop-helix region in CIB1 were mutated. The 
following mutations are present in all *bHLH constructs (referred to as ‘B’ in the *bHLH 
column of Fig. 10): R175A, G176A, R187A, and R189A 
Section V: Epigenetic modification and gene repression using TALEs and LITEs 
 
We sought to further expand the range of transcriptional processes addressable by 
TALE and LITE. We developed a TALE-repressor by fusing TALEs to a 4X 
concatenation of the transcriptional repressor mSin3 interaction domain (SID4X). We 
observed that, in a manner analogous to TALE-activator constructs, TALE-SID4X could 
repress endogenous transcription when targeted to the promoter of a gene of interest (Fig. 
13). 
 
Figure 13 | TALE SID4X repressor characterization and application in neurons. a, A 
synthetic repressor was constructed by concatenating 4 SID domains (SID4X). To identify the 
optimal TALE-repressor architecture, SID or SID4X was fused to a TALE designed to target the 
mouse p11 (also known as S100a10) gene. b, Fold decrease in p11 mRNA was assayed using 
qRT–PCR (mean  ±  s.e.m.; n = 3 biological replicates). c, General schematic of constitutive TALE 
transcriptional repressor packaged into AAV. Effector domain SID4X is highlighted. hSyn, 
human synapsin promoter; 2A, Thosea asigna virus 2A self-cleaving peptide36; WPRE, 
woodchuck hepatitis post-transcriptional response element; bGH pA, bovine growth hormone 
poly-A signal. phiLOV2.137 (330  bp) was chosen as a shorter fluorescent marker to ensure 
efficient AAV packaging. d, A TALE targeting either the endogenous mouse 
locus Grm5 or Grm2 was fused to SID4X and virally transduced into primary neurons. SID4X-
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mediated target gene downregulation is shown for each TALE relative to levels in control 
neurons expressing GFP only (mean  ±  s.e.m.; n = 3–4 biological replicates). 
 
 We further hypothesized that TALE-mediated targeting of histone effectors, such as SID, 
to endogenous loci could induce specific epigenetic modifications, which would enable 
the interrogation of epigenetic as well as transcriptional dynamics (Fig. 14a). We fused 
CRY2PHR with SID4X (Fig. 14b) and observed light-mediated transcription repression 
of Grm2 in neurons (Fig. 14c) accompanied by ~2-fold reduction in H3K9 acetylation at 
the targeted Grm2 promoter (Fig. 14d).  
 
Figure 14 | LITE mediated epigenetic modifications. a, LITE epigenetic modifiers 
(epiLITE). b, epiLITE AAV vectors. c, epiLITE-mediated repression of endogenous Grm2 in 
neurons (mean  ±  s.e.m; n = 4 biological replicates). d, epiLITE-mediated decrease in H3K9 
histone acetylation at the Grm2 promoter (mean  ±  s.e.m; n = 4 biological replicates). 
 
In order to expand the diversity of histone residue targets for locus-specific histone 
modification, we next derived a set of 32 repressive histone effector domains 
(Supplementary Tables 1-5). Selected from across a wide phylogenetic spectrum, the 
Figure 13 (Continued) 
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domains include histone deacetylases (HDACs), methyltransferases (HMTs), 
acetyltransferase (HAT) inhibitors, as well as HDAC and HMT recruiting proteins. 
Preference was given to proteins and functional truncations of small size to facilitate 
efficient AAV packaging. The resulting epigenetic mark-modifying TALE-histone 
effector fusion constructs (epiTALEs) were evaluated in primary neurons and Neuro 2a 
cells for their ability to repress Grm2 and Neurog2 transcription, respectively (Fig. 15 
and Fig. 16). In primary neurons, 23 out of 24 epiTALEs successfully repressed 
transcription of Grm2 (p < 0.05). Similarly, epiTALE expression in Neuro 2a cells led to 
decreased Neurog2 expression for 20 of the 32 histone effector domains tested (Fig. 16; p 
< 0.05). We then expressed a subset of promising epiTALEs in primary neurons and 
Neuro 2a cells and quantified the relative histone residue mark levels at the target locus 
using ChIP-RT-qPCR (Fig. 15 and Fig. 17). The effector domains characterized by ChIP-
RT-qPCR are listed with their corresponding histone marks and species of origin 
(Supplementary Tables 1-5). These domains provide a ready source of epigenetic 
effectors for LITE-mediated control of specific epigenetic modifications. 
 
Figure 15 | TALE-mediated epigenetic modifications in primary neurons. a, b, epiTALE 
methyltransferases mediated decrease in Grm2 mRNA and corresponding enrichment of 
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H3K9me1, H4K20me3 and H3K27me3 at the Grm2 promoter (n = 3 biological replicates). c, d, 
epiTALE histone deacetylases mediated repression of Grm2 and corresponding decreases in 
H4K8Ac and H3K9Ac marks at the Grm2 promoter (n=2–5 biological replicates). Mean  ±  s.e.m. 
in all panels. 
 
 
Figure 16 | Transcriptional repression by a diverse set of epiTALEs. a, 24 different histone 
effector domains were each fused to a Grm2 targeting TALE. TALE–effector fusions were 
expressed in primary cortical mouse neurons using AAV transduction. Grm2 mRNA levels were 
measured using qRT–PCR relative to neurons transduced with GFP only. (*p  <  0.05; mean ± 
s.e.m.; n = 2–3 biological replicates.) b, A total of 32 epiTALEs were transfected into Neuro 2a 
Figure 15 (Continued) 
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cells. 20 of them mediated significant repression of the targeted Neurog2 locus (*p  <  0.05; 
mean  ±  s.e.m.; n = 2–3 biological replicates). 
 
 
Figure 17 | EpiTALE mediated transcriptional repression and histone modifications in 
Neuro 2a cells. a, TALEs fused to histone-deacetylating epigenetic effectors NcoR and SIRT3 
targeting the murine Neurog2 locus in Neuro 2a cells were assayed for repressive activity on 
Neurog2 transcript levels (mean  ±  s.e.m.; n = 2–3 biological replicates). b, ChIP qRT–PCR 
showing a reduction in H3K9 acetylation at the Neurog2 promoter for NcoR and SIRT3 
epiTALEs (mean  ±  s.e.m.; n = 2–3 biological replicates). c, The epigenetic effector PHF19 with 
known histone methyltransferase binding activity was fused to a TALE targeting Neurog2. 
Repression of Neurog2 mRNA levels was observed (mean  ±  s.e.m.; n = 2–3 biological 
replicates). d, ChIP qRT–PCR showing an increase in H3K27me3 levels at the Neurog2 promoter 
for the PHF19 epiTALE (mean  ±  s.e.m.; n = 2–3 biological replicates)
Figure 16 (Continued) 
Section VI: CRISPR/Cas9 transcriptional effectors and CasLITEs 
 
The CRISPR/Cas9 RNA-guided nuclease system has facilitated major increases 
in the efficiency22, 38, 39, speed40, and scalability41 of mammalian genome engineering. 
The capacity for Cas9 to be targeted to a specific genetic locus using a short, typically 20 
bp, RNA guide sequence fused to a <100 bp chimeric backbone, together called a 
synthetic guide RNA (sgRNA) enables the rapid generation of distinct targeting 
sequences. Panels of greater than 800 guide sequences have been tested in a high-
throughput arrayed format38, while mixed libraries of up to 90,000 guides have been 
applied to pooled knockout screens for fundamental cellular processes42 and 
chemotherapeutic resistance41. Further, the small size of the sgRNA allows for 
convenient multiplexing of guides targeted to a single22, 23, 43 or several genetic targets22, 
23, 44. The ease of synthesis and potential for multiplexing of sgRNAs have made 
CRISPR/Cas9 systems an attractive successor to TALE based DNA-editing and 
transcriptional modulation. 
 
The discovery of a nucleolytically inactive Cas9 mutant27 (mutations D10A and H840A) 
inspired us, and our colleagues in the field26, 45-48, to explore the use of dead Cas9 (dCas9) 
as a transcriptional modulator. In principle, dCas9 is fused to an effector domain and 
expressed in concert with an sgRNA targeted to the promoter of a gene of interest. When 
the complex is expressed in a cell, the dCas9 facilitates the interaction of the sgRNA with 
chromosomal DNA, the guide sequence pairs with its target site, stabilizes the 
interaction, and allows the effector domain to act (Fig. 18a). To test this concept, we 
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fused dCas9 to either the VP64 activator domain or the SID4X repressor domain and 
selected guide sequences to target human genetic loci (Fig. 18b–d). Expression of dCas9-
VP64 with an sgRNA targeted to the KLF4 promoter resulted in up to 2.5 fold activation 
in 293FT cells, depending on the particular guide sequence of the sgRNA (Fig. 18f). 
Similarly, expression of SID4X-dCas9 with an sgRNA targeted to the promoter or 5’ 
UTR of SOX2 resulted in up to 2 fold repression, again depending on the sgRNA guide 
sequence (Fig. 18g).  
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Figure 18 | RNA-guided DNA binding protein Cas9 targeting of transcription effector 
domains to specific genomic loci. a, The RNA-guided nuclease Cas9 from the type II 
Streptococcus pyogenes CRISPR/Cas system can be converted into a nucleolytically inactive 
RNA-guided DNA binding protein (dCas9) by introducing two alanine substitutions (D10A and 
H840A). Schematic showing that a synthetic guide RNA (sgRNA) can direct dCas9-effector 
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fusion to a specific locus in the human genome. The sgRNA contains a 20-bp guide sequence at 
the 5′ end, which specifies the target sequence. On the target genomic DNA, the 20-bp target site 
needs to be followed by a 5′-NGG PAM motif. b, c, Schematics showing the sgRNA target sites 
in the human KLF4 and SOX2 loci, respectively. Blue bars indicate target sites. Magenta bars 
indicate PAM sequences. d, e, Schematics of the dCas9–VP64 transcription activator and 
SID4X–dCas9 transcription repressor constructs. f, g, dCas9–VP64 and SID4X–dCas9 mediated 
activation of KLF4 and repression of SOX2, respectively. All mRNA levels were measured 
relative to GFP transfected 293FT cells (mean  ±  s.e.m.; n = 3 biological replicates). 
 
To further validate our CRISPR/Cas9 activator approach, we expressed dCas9-VP64 in 
mouse Neuro 2a cells in combination with one of several sgRNAs targeted to the mouse 
Neurog2 locus (Supplementary Table 11). We found that 6 out of 7 guides facilitated 
significant upregulation in Neurog2 expression with the most potent guide producing ~20 
fold expression (Fig. 19). We also verified the activity of a set of previously published 
guides targeted to several human genes and found that our dCas9-VP64 system produced 
results similar to those published by our colleagues43, 47 (Fig. 20, Supplementary Table 
11). 
 
Figure 19 | dCas9 activation of murine Neurog2. sgRNA0001-0007 were designed to target the 
proximal regions of the mouse Neurog2 locus. sgRNA0001 overlapped the transcription start site 
Figure 18 (Continued) 
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(TSS) Neurog2. sgRNA0002-0006 were distributed throughout the 300 bp region upstream of the 
TSS. sgRNA0007 was located at bp 25 to 44 downstream of the TSS, within the Neurog2 5’ 
untranslated region (UTR). sgRNA0002 overlapped the TATA-box site of the Neurog2 promoter. 
Each sgRNA was expressed in combination with dCas9-VP64 in Neuro 2a cells. “No sgRNA” 
condition was transfected with an identical mass of dCas9-VP64 plasmid, as in sgRNA 




Figure 20 | CRISPR/dCas9 mediated human gene activation using validated sgRNA 
sequences. a-d, All sgRNAs were contransfected with dCas9-VP64 in 293FT cells. Fold 
expression was calculated relative to cells transfected with GFP only (mean  ±  s.e.m.; n=3 
biological replicates). a, Guide sequences sgRNA0008-0009, known to increase VEGF 
concentration as previously measured by ELISA assay47, were verified as expression activators of 
human VEGFA b-d, Guide sequences sgRNA0010-0011, sgRNA0012-0013, and sgRNA0014-
Figure 19 (Continued) 
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0015, known to increase NTF347, ASCL143, and MYOD143 expression, respectively, were 
verified as expression activators of their target genes. 
 
In order to outfit the CRISPR/Cas9 activator system with the inducible properties of our 
TALE based LITE system, we constructed a cryptochrome heterodimer and dCas9 based 
light-inducible transcriptional effector called CasLITE. The CasLITE system comprises 
three components: a dCas9-CIB1 fusion protein, a CRY2PHR-effector fusion protein, 
and an sgRNA (Fig. 21). The dCas9-CIB1 forms a complex with the sgRNA to provide 
targeting to the gene of interest. Upon photostimulation, the CRY2PHR/CIB1 binding 
event localizes the effector domain to the target locus, inducing transcriptional 
modulation.  
 
Figure 21 | Overview of CasLITE activation. dCas9-CIB1, in complex with an sgRNA, guides 
the system to the target locus via base-pairing of the sgRNA guide sequence with DNA at the 
gene of interest. Blue light stimulation induces CRY2/CIB1 dimerization, recruiting the effector 
domain to the target promoter.  
 
We tested several versions of a VP64 activator CasLITE system with guides targeted, 
independently, to human ASCL1, MYOD1, and IL1RN (Fig. 22). We found that one 
iteration, CasLITE1.0 2X NLS, designed from our initial LITE CIB1/CRY2PHR system 
but using a double NLS linker, produced the highest absolute activation. Another version 
Figure 20 (Continued) 
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of the system, CasLITE2.0, based on the inducible nuclear import LITE 2.0 system, 
resulted in both a lower activation level and a lower background signal. Fold induction 
was observed to be highly variable between gene targets, which future iterations of the 
system will aim to improve.  
 
Figure 22 | Light-inducible RNA-guided transcriptional activation using CasLITEs. Several 
versions of the CasLITE system were tested for their capacity to provide light-mediated 
activation of human genes in 293FT cells. CasLITE1.0 was modeled after the basic 
CRY2PHR/CIB1 LITE architecture, with a single NLS between the CRY2PHR and VP64 
domains and either a single or double NLS between the dCas9 and CIB1 domains. CasLITE2.0 
was modeled after the LITE2.0 architecture for light-inducible nuclear import, with an NLS at 
both the N-term and C-term of CRY2PHR and a GS linker between the dCas9 and CIB1 
domains. All fold expression levels were calculated by comparison to light-stimulated cells 
expressing GFP only (mean  ±  s.e.m.; n=3 biological replicates). a, sgRNA0012, which targets the 
ASCL1 locus, was co-expressed with each version of the CasLITE system. b, sgRNA0014, which 
targets the MYOD1 locus, was co-expressed with each version of the CasLITE system. c, 4 
sgRNAs designed to target the IL1RN locus were co-expressed with each version of the CasLITE 
system. 
 
To expand the applicability of the constitutive CRISPR/Cas9 activator approach to a wide 
range of biological applications, such as genome-wide activation screens, the potency of 
individual sgRNA/dCas9-activator combinations must be enhanced. We hypothesized 
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that the activation potency of current CRISPR/Cas9 activators may be hindered by the 
placement of the activator domain at either the N- or C-term of the dCas9. In fact, 
observation of the Cas9/DNA/RNA crystal structure49 suggested that a VP64 domain 
fused to either terminus would be poorly localized to the target DNA.  
 
Further observation of the crystal structure suggested that the sgRNA stemloops are not 
occluded by Cas9 and are in close proximity to the target DNA. By modifying these 
stemloops to become transcriptional activator recruitment sites, we hoped to improve the 
potency of the CRISPR/Cas9 actvators. To do so, we employed the MS2 phage coat 
protein, which binds directly to a particular RNA sequence50-53. We designed modified 
sgRNA backbones, with an MS2 binding site inserted into the native sgRNA stemloop 
sites (Fig. 23a). An MS2 binding site replaced either the sgRNA tetraloop or stemloop 2 
or both. The first iteration of the system consisted of 3 components: dCas9, an sgRNA 
with an inserted MS2 site(s), and an MS2-VP64 fusion protein. The dCas9-VP64/sgRNA 
complex localizes to the gene of interest while the MS2-VP64 binds to its site on the 
sgRNA and induces transcription. When targeted to the mouse Neurog2 locus in Neuro 
2a cells, a more potent activation, compared to the basic dCas9-VP64 system, was 
observed in all conditions that included both the MS2-VP64 and an MS2 binding site in 
the sgRNA (Fig. 23b). The combination of MS2-VP64, dCas9-VP64, and an sgRNA 
with MS2 binding sites at both the tetraloop and stemloop 2 resulted in an ~8 fold 




Figure 23 | MS2-VP64 mediated transcriptional activation. a, Schematic of the MS2-effector 
and MS2 sgRNA interaction. The tetraloop and/or stem-loop 2 of the standard chimeric sgRNA 
were replaced with the sequence encoding an MS2 binding site. These binding sites promote the 
recruitment of an MS2 phage coat protein, which was fused to the VP64 activation domain. b, 
Three component combinations of sgRNA, MS2-VP64, and dCas9 were tested for their ability to 
activate expression from the mouse Neurog2 locus. The target sequence sgRNA0003 was inserted 
into several sgRNA backbones: an sgRNA backbone containing an MS2 binding site at the 
tetraloop and/or stem-loop 2, as well as the standard sgRNA backbone, which contained no MS2 
binding site. Each of these sgRNAs was co-expressed with MS2-VP64 and either dCas9 with no 
effector domain or dCas9-VP64. Fold Neurog2 expression was calculated relative to cells 
expressing GFP only (mean  ±  s.e.m.; n=3 biological replicates). 
 
The design of the MS2/dCas9 activator system opens the door for the use of independent 
effector domains on the dCas9-activator and the MS2-activator. We hypothesized that 
greater activation levels could be achieved by placing distinct, complimentary activation 
domains on the dCas9 and MS2 proteins. We created proteins with MS2 and dCas9 fused 
to either VP64 or the p65 activation domain. Interestingly, we found that, when used in 
combination, the p65 and VP64 effectors produced greater levels of activation than 
versions of the system consisting of an equivalent number of a single type of activator 
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domain (Fig. 24). All told, the combination of MS2-p65, dCas9-VP64, and an sgRNA 
with two MS2 binding sites produced ~500 fold activation when targeted to human 
ASCL1 in 293FT cells, compared to 15 fold activation using our standard dCas9-VP64 
and standard sgRNA. Comparatively, activation of human MYOD1 increased from ~40 
fold under the standard system to ~170 fold when targeted by the MS2-p65/dCas9-VP64 
combination. Given the increased potency of the MS2/dCas9 activator and its capacity 
for synergistic complimentary effector domain recruitment, we believe this architecture 
offers an attractive alternative to previous CRISPR/Cas9 transcriptional effector 
approaches. 
 
Figure 24 | Dual recruitment of p65 and VP64 activation domains by the 
MS2/CRISPR/dCas9 activator system. Three component combinations of an sgRNA, MS2-
activator, and dCas9 were tested for their ability to activate human genes of interest in 293FT 
cells. Modified MS2 sgRNA backbones contained an MS2 binding site at the tetraloop and/or 
stem-loop 2 of the sgRNA. The standard sgRNA contained no MS2 binding site. Cells received 
either the MS2-VP64 or MS2-p65 activator protein. Cells also received either dCas9 with no 
effector domain, dCas9-VP64, or dCas9-p65. Conditions marked with “None” or “No MS2”, 
received an empty pUC19 expression plasmid instead of an sgRNA plasmid or MS2-activator 
plasmid, respectively. Fold gene expression was determined relative to cells expressing GFP only 
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(mean  ±  s.e.m.; n=2–3 biological replicates). a, Guide sequence sgRNA0012, targeted to the 
human ASCL1 locus, was tested with each combination of the MS2/CRISPR/dCas9 activator 
system. b, Guide sequence sgRNA0014, targeted to the human MYOD1 locus, was tested with 
each combination of the MS2/CRISPR/dCas9 activator system.
Figure 24 (Continued) 
Section VII: Considerations and Continuations 
 
In considering this work, it is worth noting some of the open questions and 
caveats of the systems we have developed. These perspectives should also shed light on 
our continuing progress towards new transcriptional engineering tools. 
 
Although we have characterized our TALE and CRISPR/Cas9 based transcriptional 
modulation tools from an engineering perspective, a number of questions remain 
regarding the basic biological responses to such systems. For instance, expression levels 
vary widely from gene to gene when activated by TALE-TFs (Fig. 5c) or dCas9-
activators (Fig. 20). Basal expression level, locus-specific epigenetic states, local 
chromatin conformation, positive and negative transcriptional feedback, amongst other 
mechanisms, may contribute to the diversity of gene-specific responses to engineered 
transcriptional modulators. A systematic study of a large panel of activation targets, 
integrating transcriptional dynamics and epigenetic data, will be necessary to elucidate 
the particular mechanisms which attenuate or amplify gene expression engineering. An 
understanding of how artificial transcription factors interact with endogenous 
transcriptional regulation processes would prove invaluable for classifying locus-specific 
regulation mechanisms and interrogating gene expression in a systematic manner.  
 
In addition to deepening our understanding of targeted activation processes, progress in 
the field will require a study of the genome-wide off-target effects of engineered 
transcriptional modulators. Significant effort has been dedicated to studying indel 
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formation by TALE54, 55 and CRISPR/Cas938 nucleases at predicted off-target sites. 
Preliminary RNA-seq data sets have also been generated for dCas9 repressors targeted to 
fluorescent reporters45 and dCas9 activators with sgRNAs targeted to the IL1RN locus43. 
However, a thorough genome-wide transcriptomic characterization is yet to be performed 
for either TALE or dCas9 based activators. For our continuing work, it will be of primary 
importance to understand any off-target effects of the MS2/dCas9 activator system. Wide 
adoption of either TALE or dCas9 transcriptional modulators will depend on a clear 
picture of off-target expression changes, as well as cytotoxicity and other cellular side-
effects, in order to ensure clean experimental results or safe therapeutic applications. 
 
As was highlighted at several points in the preceding sections (Fig. 2c and d, Fig. 7), 
light intensity is a critical parameter for the LITE system. We have observed that 
differences in tissue contexts can affect the light dosage tolerance of stimulated cells. It is 
likely that each individual cell line and primary tissue type will possess unique light 
sensitivity characteristics. Cell types could also exhibit markedly different light 
sensitivities within in vitro and in vivo contexts. Moving beyond viability studies, subtler 
analyses of photosensitivity, including gene expression analysis, would expand our 
understanding of the cell-physiological effects of the LITE system. 
 
Complementary to elucidating the critical biological questions discussed above, we hope 
that our continuing work will yield further engineering improvements to increase the 
utility of the systems we have developed. For instance, the incorporation of photodimers 
that can be activated by wavelengths outside of the blue spectrum would open the door to 
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multimodal expression modulation of multiple genes. Capitalizing on the modularity of 
our TALE and dCas9 based architectures, we aim to continue to expand the toolbox of 
domains that we can apply to transcriptional and epigenetic engineering by testing 
effectors from across the phylogenetic spectrum. 
 
There are a number of characterizations and improvements necessary to continue the 
development of dCas9 transcriptional modulators. Decoupling locus-specific regulation 
mechanisms from the variability in activator efficiency defined by targeting sequence 
content and location will facilitate a more rational approach to transcriptional modulator 
design. Testing our MS2/dCas9 system at a greater diversity of targets will allow us to 
evaluate the robustness this new iteration. Utilizing the MS2/dCas9 architecture to push 
the boundaries of gene activation multiplexing would help realize one of the main 
advantages supposedly offered by RNA-guided transcriptional effector systems. 
Assessing whether the high levels of transcription that we have observed using the 
MS2/dCas9 system are translated to the protein level is a key pending question in our 
current work. Looking ahead, porting the MS2/dCas9 system to lentiviral and AAV 
delivery systems will expand the diversity of contexts in which we can apply this new set 
of tools. Finally, the development of a virally delivered MS2/dCas9 activator system that 
can robustly activate expression using single sgRNA sequences will allow us to pursue 
genome-wide transcriptional activation screening applications. We believe that such a 
transcriptional modulation system, capable of interrogating large pathways or whole 
transcriptomes, will enable previously unachievable systems-level approaches to 
understanding gene expression dynamics.  
Section VIII: Materials and Methods 
 
Design and construction of LITEs 
All LITE constructs sequences can be found in Supplementary Sequences. We 
evaluated full-length CRY2 as well as a truncation consisting of the photolyase homology 
region alone (CRY2PHR, amino acids 1-498)6. For CIB1, we tested the full-length 
protein as well as an N-terminal domain-only fragment (CIBN, amino acids 1-170)6. The 
efficacy of each design was determined based on the level of light-dependent up-
regulation of the endogenous target Neurog2 mRNA (Fig. 1b). In order to use AAV as a 
vector for the delivery of LITE components, we needed to ensure that the total viral 
genome size of each recombinant AAV, with the LITE transgenes included, did not 
exceed the packaging limit of 4.8 kb56. We shortened the TALE N- and C-termini 
(keeping 136 aa in the N-terminus and 63 aa in the C-terminus) and exchanged the 
CRY2PHR (1.5kb) and CIB1 (1kb) domains (TALE-CIB1 and CRY2PHR-VP64; Fig. 
6a). TALE binding sequences were selected based on Dnase I-sensitive regions in the 
promoter of each target gene. TALE targeting sequences are listed in Supplementary 
Table 6. 
 
Neuro 2a culture and experiments 
Neuro 2a cells (Sigma-Aldrich) were grown in media containing a 1:1 ratio of OptiMEM 
(Life Technologies) to high-glucose DMEM with GlutaMax and Sodium Pyruvate (Life 
Technologies) supplemented with 5% HyClone heat-inactivated FBS (Thermo 
Scientific), 1% penicillin/streptomycin (Life Technologies), and passaged at 1:5 every 2 
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days. 120,000 cells were plated in each well of a 24-well plate 18-20 h prior to 
transfection. 1 h before transfection, media was changed to DMEM supplemented with 
5% HyClone heat-inactivated FBS and 1% penicillin/streptomycin. Cells were 
transfected with 1.0 µg total of construct DNA (at equimolar ratios) per well with 1.5 µL 
of GenJet (SignaGen Laboratories) transfection reagent according to the manufacturer’s 
instructions. Media was exchanged 24 h and 44 h post-transfection and light stimulation 
was started at 48 h. Stimulation parameters were: 5 mW cm-2, 466 nm, 7 % duty cycle (1 
s light pulse 0.067 Hz) for 24 h unless indicated otherwise in figure legends. RNA was 
extracted using the Rneasy kit (Qiagen) according to manufacturer’s instructions and 1 
µg of RNA per sample was reverse-transcribed using qScript (Quanta Biosystems). 
Relative mRNA levels were measured by quantitative real-time PCR (qRT-PCR) using 
TaqMan probes specific for the targeted gene as well as GAPDH as an endogenous 
control (Life Technologies, see Supplementary Table 7 for Taqman probe IDs). ΔΔCt 
analysis was used to obtain fold-changes relative to negative controls transduced with 
GFP only and subjected to light stimulation. Toxicity experiments were conducted using 
the LIVE/DEAD assay kit (Life Technologies) according to manufacturer’s protocol. 
 
AAV vector production 
The ssDNA-based genome of AAV is less susceptible to recombination, thus providing 
an advantage over RNA-based lentiviral vectors for the packaging and delivery of highly 
repetitive TALE sequences33. 293FT cells (Life Technologies) were grown in antibiotic-
free D10 media (DMEM high glucose with GlutaMax and Sodium Pyruvate, 10% heat-
inactivated Hyclone FBS, and 1% 1M HEPES) and passaged daily at 1:2-2.5. The total 
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number of passages was kept below 10 and cells were never grown beyond 85% 
confluence. The day before transfection, 1x106 cells in 21.5 mL of D10 media were 
plated onto 15 cm dishes and incubated for 18-22 hours or until ~80% confluence. For 
use as a transfection reagent, 1 mg/mL of PEI “Max” (Polysciences) was dissolved in 
water and the pH of the solution was adjusted to 7.1. For AAV production, 10.4 µg of 
pDF6 helper plasmid, 8.7 µg of pAAV1 serotype packaging vector, and 5.2 µg of pAAV 
vector carrying the gene of interest were added to 434 µL of serum-free DMEM and 130 
µL of PEI “Max” solution was added to the DMEM-diluted DNA mixture. The 
DNA/DMEM/PEI cocktail was vortexed briefly and incubated at room temperature for 
15 min. After incubation, the transfection mixture was added to 22 mL of complete 
media, vortexed briefly, and used to replace the media for a 15 cm dish of 293FT cells. 
For supernatant production, transfection supernatant was harvested at 48 h, filtered 
through a 0.45 µm PVDF filter (Millipore), distributed into aliquots, and frozen for 
storage at -80°C. 
 
Primary cortical neuron culture 
Dissociated cortical neurons were prepared from C57BL/6N mouse embryos on E16 
(Charles River Labs). Cortical tissue was dissected in ice-cold HBSS – (50 mL 10x 
HBSS, 435 mL dH2O, 0.3 M HEPES pH 7.3, and 1% penicillin/streptomycin). Cortical 
tissue was washed 3X with 20 mL of ice-cold HBSS and then digested at 37°C for 20 
min in 8 mL of HBSS with 240 µL of 2.5% trypsin (Life Technologies). Cortices were 
then washed 3 times with 20 mL of warm HBSS containing 1 mL FBS. Cortices were 
gently triturated in 2 ml of HBSS and plated at 150,000 cells/well in poly-D-lysine coated 
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24-well plates (BD Biosciences). Neurons were maintained in Neurobasal media (Life 
Technologies), supplemented with 1X B27 (Life Technologies), GlutaMax (Life 
Technologies) and 1% penicillin/streptomycin. 
 
Primary neuron transduction and light stimulation experiments 
Primary cortical neurons were transduced with 250 µL of AAV1 supernatant on DIV 5. 
The media and supernatant were replaced with regular complete neurobasal the following 
day. Neurobasal was exchanged with Minimal Essential Medium (Life Technologies) 
containing 1X B27, GlutaMax (Life Technologies) and 1% penicillin/streptomycin 6 
days after AAV transduction to prevent formation of phototoxic products from HEPES 
and riboflavin contained in Neurobasal during light stimulation. For co-transduction of 
primary neurons with two AAV vectors, the co-delivery efficiency was >80%, with 
individual components having transduction efficiencies of 83-92%. 
 
Light stimulation was started 6 days after AAV transduction (DIV 11) with an intensity 
of 5 mW/cm2, duty cycle of 0.8% (250 ms pulses at 0.033Hz or 500 ms pulses at 
0.016Hz), 466 nm blue light for 24 h unless indicated otherwise in figure legends. RNA 
extraction and reverse transcription were performed using the Cells-to-Ct kit according to 
the manufacturers instructions (Life Technologies). Relative mRNA levels were 
measured by quantitative real-time PCR (qRT-PCR) using TaqMan probes as described 
above for Neuro 2a cells. 
 
Immunohistochemistry of primary neurons 
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For immunohistochemistry of primary neurons, cells were plated on poly-D-
lysine/laminin coated coverslips (BD Biosciences) after harvesting. AAV1 transductions 
were performed as described above. Neurons were fixed 7 days post-transduction with 
4% paraformaldehyde (Sigma Aldrich) for 15 min at room temperature. Blocking and 
permeabilization were performed with 10% normal goat serum (Life Technologies) and 
0.5% Triton-X100 (Sigma-Aldrich) in DPBS (Life Technologies) for 1 h at room 
temperature. Neurons were incubated with primary antibodies overnight at 4°C, washed 
3X with DPBS and incubated with secondary antibodies for 90 min at RT. For antibody 
providers and concentrations used, see Supplementary Table 8. Coverslips were finally 
mounted using Prolong Gold Antifade Reagent with DAPI (Life Technologies) and 
imaged on an Axio Scope A.1 (Zeiss) with an X-Cite 120Q light source (Lumen 




For preparation of total protein lysates, primary cortical neurons were harvested after 
light stimulation in ice-cold lysis buffer (RIPA, Cell Signaling; 0.1% SDS, Sigma-
Aldrich; and cOmplete ULTRA protease inhibitor mix, Roche Applied Science). Cell 
lysates were sonicated for 5 min at ‘M’ setting with the Bioruptor water bath sonicator 
(Diagenode) and centrifuged at 21,000 x g for 10 min at 4°C.  Protein concentration was 
determined using the RC DC protein assay (Bio-Rad). 30-40 µg of total protein per lane 
was separated under non-reducing conditions on 4-15% Tris-HCl gels (Bio-Rad) along 
with Precision Plus Protein Dual Color Standard (Bio-Rad). After wet electrotransfer to 
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polyvinylidene difluoride membranes (Millipore) and membrane blocking for 45 min in 
5% BLOT-QuickBlocker (Millipore) in Tris-buffered saline (TBS, Bio-Rad), western 
blots were probed with anti-mGluR2 (Abcam, 1:1.000) and anti-α-tubulin (Sigma-
Aldrich 1:20,000) overnight at 4°C, followed by washing and anti-mouse-IgG HRP 
antibody incubation (Sigma-Aldrich, 1:5,000 – 1:10,000). For further antibody details see 
Supplementary Table 8. Detection was performed via ECL Western blot substrate 
(SuperSignal West Femto Kit, Thermo Scientific). Blots were imaged with an 
AlphaImager system (Innotech), and quantified using ImageJ software 1.46r. 
 
Production of concentrated and purified AAV1/2 vectors 
Production of concentrated and purified AAV for stereotactic injection in vivo was 
performed using the same initial steps outlined above for production of AAV1 
supernatant. However, for transfection, equal ratios of AAV1 and AAV2 serotype 
plasmids were used instead of AAV1 alone. Five 15cm plates were transfected per 
construct and cells were harvested with a cell-scraper 48 h post transfection. Purification 
of AAV1/2 particles was performed using HiTrap heparin affinity columns (GE 
Healthcare)57. We added a second concentration step down to a final volume of 100 µl 
per construct using an Amicon 500 µl concentration column (100 kDa cutoff, Millipore) 
to achieve higher viral titers. Titration of AAV was performed by qRT-PCR using a 
custom Taqman probe for WPRE (Life Technologies). Prior to qRT-PCR, concentrated 
AAV was treated with DnaseI (New England Biolabs) to achieve a measurement of 
DnaseI-resistant particles only. Following DnaseI heat-inactivation, the viral envelope 
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was degraded by Proteinase K digestion (New England Biolabs). Viral titer was 
calculated based on a standard curve with known WPRE copy numbers. 
 
Stereotactic injection of AAV1/2 and optical implant   
All animal procedures were approved by the MIT Committee on Animal Care. Adult (10-
14 weeks old) male C57BL/6N mice were anaesthetized by intraperitoneal (i.p.) injection 
of Ketamine/Xylazine (100 mg/kg Ketamine and 10 mg/kg Xylazine) and pre-emptive 
analgesia was applied (Buprenex, 1 mg/kg, i.p.). Craniotomy was performed according to 
approved procedures and 1µl of AAV1/2 was injected into ILC at 0.35/1.94/-2.94 
(lateral, anterior and inferior coordinates in mm relative to bregma). During the same 
surgical procedure, an optical cannula with fiber (Doric Lenses) was implanted into ILC 
unilaterally with the end of the optical fiber located at 0.35/1.94/-2.64 relative to bregma. 
The cannula was affixed to the skull using Metabond dental cement (Parkell Inc) and Jet 
denture repair (Lang Dental) to build a stable, supporting cone. The incision was sutured 
and proper post-operative analgesics were administered for three days following surgery.  
 
Immunohistochemistry on ILC brain sections 
Mice were injected with a lethal dose of Ketamine/Xylazine anaesthetic and 
transcardially perfused with PBS and 4% paraformaldehyde (PFA). Brains were 
additionally fixed in 4% PFA at 4°C overnight and then transferred to 30% sucrose for 
cryoprotection overnight at room temperature. Brains were then transferred into Tissue-
Tek Optimal Cutting Temperature (OCT) Compound (Sakura Finetek) and frozen at -
80°C. 18 µm sections were cut on a cryostat (Leica Biosystems) and mounted on 
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Superfrost Plus glass slides (Thermo Fischer). Sections were post-fixed with 4% PFA for 
15 min, and immunohistochemistry was performed as described for primary neurons 
above.   
 
Light stimulation and mRNA level analysis in ILC 
Neurons at the injection site were efficiently co-transduced by both viruses, with >80% of 
transduced cells expressing both TALE(Grm2)-CIB1 and CRY2PHR-VP64 (Fig. 8b and 
c). 8 days post-surgery, awake and freely moving mice were stimulated using a 473 nm 
laser source (OEM Laser Systems) connected to the optical implant via fiber patch cables 
and a rotary joint. Stimulation parameters were the same as used on primary neurons: 5 
mW (total output), 0.8% duty cycle (500 ms light pulses at 0.016 Hz) for a total of 12 h. 
Brain tissue from the fiber optic cannula implantation site was analyzed (Fig. 3h) for 
changes in Grm2 mRNA. Experimental conditions, including transduced constructs and 
light stimulation are listed in Supplementary Table 9. 
 
After the end of light stimulations, mice were euthanized using CO2 and the prefrontal 
cortices (PFC) were quickly dissected on ice and incubated in RNA later (Qiagen) at 4°C 
overnight. 200 µm sections were cut in RNA later at 4°C on a vibratome (Leica 
Biosystems). Sections were then frozen on a glass coverslide on dry ice and virally 
transduced ILC was identified under a fluorescent stereomicroscope (Leica M165 FC). A 
0.35 mm diameter punch of ILC, located directly ventrally to the termination of the 
optical fiber tract, was extracted (Harris uni-core, Ted Pella). The brain punch sample 
was then homogenized using an Rnase-free pellet-pestle grinder (Kimble Chase) in 50 µl 
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Cells-to-Ct RNA lysis buffer and RNA extraction, reverse transcription and qRT-PCR 
was performed as described for primary neuron samples.   
 
Chromatin Immunoprecipitation 
Neurons or Neuro 2a cells were cultured and transduced or transfected as described 
above. ChIP samples were prepared as previously described58 with minor adjustments for 
the cell number and cell type. Cells were harvested in 24-well format, washed in 96-well 
format, and transferred to microcentrifuge tubes for lysis. Sample cells were directly 
lysed by water bath sonication with the Biorupter sonication device for 21 minutes using 
30s on/off cycles (Diagenode). qPCR was used to assess enrichment of histone marks at 
the targeted locus. qPCR primer sequences are listed in Supplementary Table 10. 
 
Statistical analysis  
All experiments were performed with a minimum of two independent biological 
replicates. Statistical analysis was performed with Prism (GraphPad) using Student’s 
two-tailed t-test when comparing two conditions, ANOVA with Tukey’s post-hoc 
analysis when comparing multiple samples with each other, and ANOVA with Dunnett’s 
post-hoc analysis when comparing multiple samples to the negative control. 
 
Photostimulation Hardware – in vitro 
In vitro light stimulation experiments were performed using a custom built LED 
photostimulation device. All electronic elements were mounted on a custom printed 
circuit board (ExpressPCB). Blue LEDs with peaks 466 nm (model #: YSL-R542B5C-
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A11, China Young Sun LED Technology; distributed by SparkFun Electronics as ‘LED – 
Super Bright Blue’ COM-00529), were arrayed in groups of three aligned with the wells 
of a Corning 24-well plate. LED current flow was regulated by a 25 mA DynaOhm driver 
(LEDdymanics #4006-025). Columns of the LED array were addressed by TTL control 
(Fairchild Semiconductor PN2222BU-ND) via an Arduino UNO microcontroller board. 
Light output was modulated via pulse width modulation. Light output was measured from 
a distance of 80 mm above the array utilizing a Thorlabs PM100D power meter and 
S120VC photodiode detector. In order to provide space for ventilation and to maximize 
light field uniformity, an 80 mm tall ventilation spacer was placed between the LED 
array and the 24-well sample plate. Fans (Evercool EC5015M12CA) were mounted along 
one wall of the spacer unit, while the opposite wall was fabricated with gaps to allow for 
increased airflow. 
 
Ambient light exposure 
All cells were cultured at low light levels (<0.01 mW/cm2) at all times except during 
stimulation. These precautions were taken as ambient light in the room (0.1-0.2 mW/cm2) 
was found to significantly activate the LITE system (Fig. 2c). No special precautions 
were taken to shield animals from light during in vivo experiments – even assuming ideal 
propagation within the implanted optical fiber, an estimation of light transmission at the 
fiber terminal due to ambient light was <0.01 mW (based on 200 µm fiber core diameter 
and 0.22 numerical aperture). 
 
Optimization of light stimulation parameters in Neuro2A cells 
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To minimize near-UV induced cytotoxicity, we selected 466 nm blue LEDs to activate 
TALE-CRY2, a wavelength slightly red-shifted from the CRY2 absorption maxima of 
450 nm but still maintaining over 80% activity29 (Fig. 2a). To minimize light exposure, 
we selected a mild stimulation protocol (1 s light pulses at 0.067 Hz, ~7% duty cycle). 
This was based on our finding that light duty cycle had no significant effect on LITE-
mediated transcriptional activation over a wide range of duty cycle parameters (1.7% to 
100% duty cycles, Fig. 2b). Illumination with a range of light intensities from 0 to 10 
mW/cm2 revealed that Ngn2 mRNA levels increased as a function of intensity up to 5 
mW/cm2.  
 
However, increases in Ngn2 mRNA levels declined at 10 mW/cm2 (Fig. 2c), suggesting 
that higher intensity light may have detrimental effects on either LITE function or on cell 
physiology. To better characterize this observation, we performed an ethidium 
homodimer-1 cytotoxicity assay with a calcein counterstain for living cells and found a 
significantly higher percentage of ethidium-positive cells at the higher stimulation 
intensity of 10 mW/cm2. Conversely, the ethidium-positive cell count from 5 mW/cm2 
stimulation was indistinguishable from unstimulated controls (Fig. 2d). Thus 5 mW/cm2 
appeared to be optimal for achieving robust LITE activation while maintaining low 
cytotoxicity. 
 
Quantification of LIVE/DEAD® assay using ImageJ software. 
Images of LIVE/DEAD (Life Technologies) stained cells were captured by fluorescence 
microscopy and processed as follows: Background was subtracted (Process  Subtract 
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Background). A threshold based on fluorescence area was set to ensure accurate 
identification of cell state (Image  Adjust  Threshold). A segmentation analysis was 
performed to enable automated counting of individual cells (Process  Binary  
Watershed). Finally, debris signals were filtered and cells were counted (Analyze  
Analyze Particles). Toxicity was determined as the percentage of dead cells.  
 
Reduction of light-induced toxicity in primary neurons 
Initial application of LITEs in neurons revealed that cultured neurons were much more 
sensitive to blue light than Neuro 2a cells. Stimulation parameters previously optimized 
for Neuro 2a cells (466 nm, 5 mW/cm2 intensity, 7% duty cycle with 1 s light pulse at 
0.067 Hz for a total of 24 h) caused >50% toxicity in primary neurons. We therefore 
tested survival with a lower duty cycle, as we had previously observed that a wide range 
of duty cycles had little effect on LITE-mediated transcriptional activation (Fig. 2b). A 
reduced duty cycle of 0.8% (0.5 s light pulses at 0.0167 Hz) at the same light intensity (5 
mW/cm2) was sufficient to maintain a high survival rate that was indistinguishable from 
that of unstimulated cultures (Fig. 7). 
 
Light propagation and toxicity in in vivo experiments 
Previous studies have investigated the propagation efficiency of different wavelengths of 
light in brain tissue. For 473 nm light (wavelength used in this study), there was a >90% 
attenuation after passing through 0.35 mm of tissue59. An estimated 5 mW/cm2 light 
power density was estimated based on a tissue depth of 0.35 mm of tissue (the diameter 
of brain punch used in this study) and a total power output of 5 mW. The light 
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stimulation duty cycle used in vivo was the same (0.8%, 0.5 s at 0.0167 Hz) as that used 
for primary neurons. 
 
Chemically-inducible TALEs  
Neuro2A cells were grown in a medium containing a 1:1 ratio of OptiMEM (Life 
Technologies) to high-glucose DMEM with GlutaMax and Sodium Pyruvate (Life 
Technologies) supplemented with 5% HyClone heat-inactivated FBS (Thermo 
Scientific), 1% penicillin/streptomycin (Life Technologies) and 25mM HEPES (Sigma 
Aldrich). 150,000 cells were plated in each well of a 24-well plate 18-24 hours prior to 
transfection. Cells were transfected with 1 µg total of construct DNA (at equimolar 
ratios) per well and 2 µL of Lipofectamine 2000 (Life Technologies) according to the 
manufacturer’s recommended protocols. Media was exchanged 12 hours post-
transfection. For the kinetics test, chemical induction was started 24 hours post-
transfection, when abscisic acid (ABA, Sigma Aldrich) was added to fresh media to a 
final concentration of 250 µM. RNA was extracted using the Rneasy kit (Qiagen) 
according to manufacturer’s instructions and 1 µg of RNA per sample was reverse-
transcribed using qScript (Quanta Biosystems). Relative mRNA levels were measured by 
quantitative real-time PCR (qRT-PCR) using Taqman probes specific for the targeted 
gene as well as mouse GAPDH as an endogenous control (Life Technologies, see 
Supplementary Table 7 for Taqman probe IDs). ΔΔCt analysis was used to obtain fold-




Development of AAV1 supernatant process 
Traditional AAV particle generation requires laborious production and purification 
processes60, making the testing of many constructs in parallel impractical. In this study, a 
simple yet highly effective process of AAV production using filtered supernatant from 
transfected 293FT cells was developed (Fig. 4). A previous study indicated that AAV 
particles produced in 293FT cells could be found not only within the cytoplasm but also 
in considerable amounts within the culture media61. The ratio of viral particles between 
the supernatant and cytosol of host cells varied depending on the AAV serotype, and 
secretion was enhanced if polyethylenimine (PEI) was used to transfect the viral 
packaging plasmids61.  
 
In the current study, we demonstrated that 2x105 293FT cells transfected with AAV 
vectors carrying TALEs (Fig. 5a) and packaged using AAV1 serotype were capable of 
producing 250 µl of AAV1 at a concentration of 5.6 ± 0.24 x 1010 DnaseI resistant 
genome copies (GC) per mL. 250 µl of filtered supernatant was able to transduce 150,000 
primary cortical neurons at efficiencies of 80-90% (Fig. 2b and Fig. 8b and c). This 
process was also successfully adapted to a 96-well format, enabling the production of 125 
µl AAV1 supernatant from up to 96 different constructs in parallel. 35µl of supernatant 
can then be used to transduce one well of primary neurons cultured in 96-well format, 
enabling transductions in biological triplicates from a single well. 
 
Cas9 transcriptional effectors: SOX2 and KLF4 experiments 
HEK 293FT cells were co-transfected with mutant Cas9 fusion protein and a synthetic 
guide RNA (sgRNA) using Lipofectamine 2000 (Life Technologies) 24 hours after 
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seeding into a 24 well dish. 72 hours post-transfection, total RNA was purified (Rneasy 
Plus, Qiagen). 1 µg of RNA was reverse transcribed into cDNA (qScript, Quanta 
BioSciences). Quantitative real-time PCR was done according to the manufacturer’s 
protocol (Life Technologies) and performed in triplicate using TaqMan Assays for hKlf4 
(Hs00358836_m1), hSox2 (Hs01053049_s1), and the endogenous control GAPDH 
(Hs02758991_g1). 
The hSpCas9 activator plasmid was cloned into a lentiviral vector under the expression of 
the hEF1a promoter (pLenti-EF1a-Cas9-NLS-VP64). The hSpCas9 repressor plasmid 
was cloned into the same vector (pLenti-EF1a-SID4x-NLS-Cas9-NLS). Guide sequences 
(20bp) targeted to the KLF4 locus are: 5’-GCGCGCTCCACACAACTCAC, 5’-
GCAAAAATAGACAATCAGCA, GAAGGATCTCGGCCAATTTG. Spacer sequences 
for guide RNAs targeted to the SOX2 locus are: 5’-GCTGCCGGGTTTTGCATGAA, 5’-
CCGGGCCCGCAGCAAACTTC, 5’-GGGGCTGTCAGGGAATAAAT 
 
Neurog2 activation with dCas9-VP64 and standard sgRNA backbone 
The locus for the mouse gene Neurog2 was selected for testing dCas9-VP64 
transcriptional activation in Neuro 2A cells. 7 sgRNA targeting sequences were selected 
from region 300 bp upstream to 100 bp downstream of the annotated Neurog2 
transcriptional start site (Supplementary Table 11). These guide sequences were cloned 
by the golden gate method into the px362 plasmid containing the U6 promoter upstream 
of a chimeric sgRNA cloning backbone.  
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Neuro 2A cells were cultured in medium consisting of a 1:1 ratio of D5 (100:5:1 DMEM 
high glucose w/Glutamax and sodium pyruvate: fetal bovine serum: 
penecilin/streptomycin). For transfection, 120,000 cells in 0.5 mL culture medium were 
plated in each well of a 24 well plate. After 22 h in culture, each well of Neuro 2A cells 
was transfected with 1 µg of DNA using 5 µL of Lipofectamine following the 
recommended steps of the manufacturer (Life Technologies). For all dCas9-VP64 + 
 sgRNA samples, 0.5 µg dCas9-VP64 plasmid and 0.5 µg sgRNA expression plasmid 
were used. For control samples, plasmid masses were replaced with GFP expressing 
plasmid as necessary. 4 h after transfection, the medium was replaced with 1 mL culture 
medium. 48 h after transfection, RNA was purified using the Macherey Nagel Nucleospin 
96 RNA kit. Reverse transcription was performed with qScript cDNA supermix 
according to the manufacturer’s protocol. qPCR was performed using Taqman probes and 
Taqman Fast Advanced Master Mix from Life Technologies on a Roche LightCycler 480 
II real-time PCR machine. 
 
Validation of human gene activation targets with dCas9-VP64 standard sgRNA 
backbone 
8 previously published sgRNA sequences43, 47 (Supplementary Table 11) were selected 
for testing in 293FT cells using our pXRP057 dCas9-VP64 activator construct. Guide 
sequences were cloned by the golden gate method into the px362 plasmid containing the 
U6 promoter upstream of a chimeric sgRNA cloning backbone.  
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293FT cells were cultured in D10 medium (100:10:1 ratio of DMEM high glucose 
w/Glutamax and sodium pyruvate: fetal bovine serum: 100x HEPES solution). For 
transfection, 100,000 cells in 0.5 mL culture medium were plated in each well of a 24 
well plate. After 22 h in culture, each well of 293FT cells was transfected with 1 µg of 
DNA using 5 µL of Lipofectamine following the recommended steps of the manufacturer 
(Life Technologies). For all dCas9-VP64 +  sgRNA samples, 0.5 µg dCas9-VP64 
plasmid and 0.5 ug sgRNA expression plasmid were used. For control samples plasmid 
masses were replaced by GFP expressing plasmid as necessary. 4 h after transfection, the 
medium was replaced with 1 mL culture medium. 48 h after transfection, RNA was 
purified using the Macherey Nagel Nucleospin 96 RNA kit. Reverse transcription was 
performed with qScript cDNA supermix according to the manufacturer’s protocol. qPCR 
was performed using Taqman probes and Taqman Fast Advanced Master Mix from Life 
Technologies on a Roche LightCycler 480 II real-time PCR machine. 
 
CasLITEs 
The CasLITE system consists of 3 components: a dCas9-CIB1 fusion protein, the 
CRY2PHR-VP64, and an sgRNA guide sequence. For the experiments described here, 3 
different versions of dCas9-CIB1 were synthesized: (1) dCas9-GS-NLS-CIB1 comprising 
the double mutant (D10A H840A) dCas9 from our pXRP057 plasmid, a glycine serine 
linker, SV40 nuclear localization signal, and CIB1 from LITE1.0. (2) dCas9-GS-NLS-
NLS-CIB1 comprising the double mutant dCas9, glycine serine linker, 2 SV40 NLS 
sequences, and CIB1 from LITE1.0. (3) dCas9-GS-CIB1(mNLS d318-334) comprising 
the double mutant dCas9, glycine serine linker from LITE2.0, and CIB1 from LITE2.0 
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sgRNA sequences targeted to ASCL1 and MYOD1, previously validated with a 
constitutive dCas9-VP64 activator, were selected for testing the CasLITE systems in 
human cells. Guide sequences were cloned by the golden gate method into the px362 
plasmid containing the U6 promoter upstream of a chimeric sgRNA cloning backbone.  
 
293FT cells were cultured in D10 medium without HEPES (10:1 ratio of DMEM high 
glucose w/Glutamax and sodium pyruvate: fetal bovine serum). For transfection, 100,000 
cells in 0.5 mL culture medium were plated in each well of a 24 well plate. After 22 h in 
culture, each well of 293FT cells was transfected with 1.5 µg of DNA using 7.5 uL of 
Lipofectamine following the recommended steps of the manufacturer (Life 
Technologies). For all CasLITE +  sgRNA samples, 0.5 µg dCas9-CIB1 plasmid, 0.5 µg 
of CRY2PHR-VP64 plasmid (LITE1.0 or LITE2.0 to match CIB1),  and 0.5 µg sgRNA 
expression plasmid were used. Experiments with 4 sgRNAs used equal masses of each of 
4 sgRNAs totaling 0.5 µg. For control samples, plasmid masses were replaced by GFP 
expressing plasmid as necessary. 4 h after transfection, the medium was replaced with 1 
mL culture medium. 48 h after transfection excitation was started on light stimulated 
samples using 5 mW/cm2 475 nm blue light. 12 h after starting stimulation, all samples, 
including all controls, were harvested for RNA using the Macherey Nagel Nucleospin 96 
RNA kit. Reverse transcription was performed with qScript cDNA supermix according to 
the manufacturer’s protocol. qPCR was performed using Taqman probes and Taqman 
Fast Advanced Master Mix from Life Technologies on a Roche LightCycler 480 II real-
time PCR machine. 
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Design and validation of MS2/dCas9 activators: Neurog2 locus 
The MS2 domain RNA binding sequence, shown in detail in Supplementary Sequences, 
was inserted into the nucleotide sequence of the standard chimeric sgRNA backbone. The 
MS2 stemloop was inserted into either the tetraloop of the sgRNA, stemloop 2 of the 
sgRNA, or into both sites49. These 3 sgRNA backbones, as well as the standard sgRNA 
backbone, were synthesized as ultramers (Integrated DNA Technologies) with the 
sgRNA0003 sequence, ATACGATGAAAAGAATAAGC, as a guide sequence targeted 
to the mouse Neurog2 promoter. The ultramers were used in combination with a U6 
promoter primer to generate PCR product38 which included, from 5’ to 3’: the U6 
promoter, the sgRNA0003 sequence, and each respective MS2 or control backbone. 
 
Neuro 2a cells (Sigma-Aldrich) were grown in media containing a 1:1 ratio of OptiMEM 
(Life Technologies) to high-glucose DMEM with GlutaMax and sodium pyruvate (Life 
Technologies) supplemented with 5% HyClone heat-inactivated FBS (Thermo 
Scientific), 1% penicillin/streptomycin (Life Technologies), and passaged at 1:5 every 2 
days. 120,000 cells were plated in each well of a 24-well plate 18–20 h before 
transfection. Cells were transfected with Lipofectamine transfection reagent (Life 
Technologies) according to the manufacturer’s instructions. Plasmid DNA was used for 
transfection of MS2-vp62 and Cas9 constructs, while PCR product was transfected for 
the guide RNA expression cassette. 48 h  after transfection, RNA was extracted using the 
Rneasy kit (Qiagen) according to manufacturer’s instructions and 1 µg of RNA per 
sample was reverse-transcribed using qScript (Quanta Biosystems). Relative mRNA 
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levels were measured by reverse transcription and quantitative PCR (qRT–PCR) using 
TaqMan probes specific for the targeted gene as well as GAPDH as an endogenous 
control (Life Technologies). ∆∆Ct analysis was used to obtain fold-changes relative to 
negative controls transfected with GFP only. 
 
MS2 1.0 Optimization: ASCL1 and MYOD1 Targets 
Human HEK293FT cells were maintained in high-glucose DMEM with GlutaMax and 
sodium pyruvate (Life Technologies) supplemented with 10% heat-inactivated 
characterized HyClone fetal bovine serum (Thermo Scientific) and 1% 
penicillin/streptomycin (Life Technologies). Cells were passaged daily at a ratio 1 to 2 or 
1 to 2.5. 20,000 HEK293FT cells were plated in 100 µL of culture medium in poly-D-
lysine coated 96-well plates (BD biosciences). 24 h after plating, cells were transfected 
with a 1:1:1 mass ratio of: 
• sgRNA backbone plasmid with gene specific targeting sequence or pUC19 
control plasmid 
• MS2-VP64 plasmid or MS2-p65 plasmid or pUC19 control plasmid 
• dCas9 plasmid or dCas9-VP64 plasmid or dCas9-p65 plasmid or pUC19 control 
plasmid 
Total plasmid mass per well was 0.3 µg. Transfection was performed with 1.5 µL 
Lipfectamine 2000 (Life Technologies), according to the manufacturer’s instructions. 
Culture medium was changed 5 h after transfection.  
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48 h after transfection, cell lysis and reverse transcription were performed using a Cells-
to-Ct kit (Life Technologies). Gene expression levels were quantified using Taqman 
qPCR probes (Life technologies) and Fast Advanced Master Mix (Life Technologies). 
ASCL1 and MYOD1 expression levels were calculated relative to GAPDH expression 
level. Fold gene expression levels were determined by comparison to samples transfected 
with GFP plasmid only. 
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Appendix A: Supplementary Tables 
 


















Sin3a MeCP2 - - R. norvegicus 492 207-49262 286 - 
Sin3a MBD2b - - H. sapiens 262 45-26263 218 - 
Sin3a Sin3a - - H. sapiens 1273 524-85164 328 627-829: 
HDAC1 
interaction 
NcoR NcoR - - H. sapiens 2440 420-48865 69 - 
NuRD SALL1 - - M. musculus 1322 1-9366 93 - 
CoREST RCOR1 - - H. sapiens 482 81-30067, 68 220 - 
 
 


















HDAC I HDAC8 - - X. laevis 325 1-325 325 1-272: 
HDAC 




MesoLo4 - - M. loti 300 1-30070 300 - 
HDAC 
IV 
HDAC11 - - H. sapiens 347 1-34771 347 14-326: 
HDAC 
HD2 HDT1 - - A. thaliana 245 1-21172 211 - 
SIRT I SIRT3 H3K9Ac 
H4K16Ac 
H3K56Ac 
- H. sapiens 399 143-39973 257 126-382: 
SIRT 
SIRT I HST2 - - C. albicans 331 1-33174 331 - 
SIRT I CobB - - E. coli (K12) 242 1-24275 242 - 
SIRT I HST2 - - S. cerevisiae 357 8-29876 291 - 
SIRT III SIRT5 H4K8Ac 
H4K16Ac 
- H. sapiens 310 37-31077 274 41-309: 
SIRT 
SIRT III Sir2A - - P. falciparum 273 1-27378 273 19-273: 
SIRT 
SIRT IV SIRT6 H3K9Ac 
H3K56Ac 























SET NUE H2B, H3, 
H4 
- C. trachomatis 219  1-21980 219 - 
SET vSET - H3K27me3 P. bursaria 
chlorella virus 



















SUV39 SUV39H1 - H3K9me2/
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Suvar4-20 SET4 - H4K20me3 C. elegans  288 1-28887 288 - 
SET8 SET1 - H4K20me1 C. elegans 242 1-24287 242 - 




SET8 TgSET8 - H4K20me1
/2/3 

























- Hp1a - H3K9me
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M. musculus 191 73-19190 119 121-179: 
chromo-
shadow 
- PHF19 - H3K27m
e3 
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Supplementary Table 7 | Taqman probes (Life Technologies) 
Target Species Probe # 
Neurog2 mouse Mm00437603_g1 
Grm5 (mGluR5) mouse Mm00690332_m1 
Grm2 (mGluR2) mouse Mm01235831_m1 
Grin2a (NMDAR2A) mouse Mm00433802_m1 
GAPD (GAPDH) mouse 4352932E 
KLF4 human Hs00358836_m1 
GAPD (GAPDH) human 4352934E 
WPRE custom  
5-HT1A mouse Mm00434106_s1 
5-HT1B mouse Mm00439377_s1 
5-HTT mouse Mm00439391_m1 
Arc mouse Mm00479619_g1 
BDNF mouse Mm04230607_s1 
c-Fos mouse Mm00487425_m1 
CBP/P300 mouse Mm01342452_m1 
CREB mouse Mm00501607_m1 
CRHR1 mouse Mm00432670_m1 
DNMT1 mouse Mm01151063_m1 
DNMT3a mouse Mm00432881_m1 
DNMT3b mouse Mm01240113_m1 
egr-1 (zif-268) mouse Mm00656724_m1 
Gad65 mouse Mm00484623_m1 
Gad67 mouse Mm00725661_s1 
GR (GCR,  NR3C1 ) mouse Mm00433832_m1 
HAT1 mouse Mm00509140_m1 
HCRTR1 mouse Mm01185776_m1 
HCRTR2 mouse Mm01179312_m1 
HDAC1 mouse Mm02391771_g1 
HDAC2 mouse Mm00515108_m1 
HDAC4 mouse Mm01299557_m1 
JMJD2A mouse Mm00805000_m1 
M1 (CHRM1) mouse Mm00432509_s1 
MCH-R1 mouse Mm00653044_m1 
NET (SLC6A2) mouse Mm00436661_m1 
NR2B subunit mouse Mm00433820_m1 
OXTR mouse Mm01182684_m1 
Scn1a mouse Mm00450580_m1 
SIRT1 mouse Mm00490758_m1 
Tet1 mouse Mm01169087_m1 
Tet2 mouse Mm00524395_m1 
Tet3 mouse Mm00805756_m1 
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Supplementary Table 8 | Antibodies 
Primary Antibodies 
Target Host Clone # Manufacturer Product # IsoType Concentration 
mGluR2 mouse mG2Na-s Abcam Ab15672 IgG 1:1000 
α-tubulin mouse B-5-1-2 Sigma-Aldrich T5168 IgG1 1:20000 




mouse 6E2 Cell Signaling 3444 IgG1 1:100 
GFP chicken polyclonal Aves Labs GFP-1020 IgY 1:500 
Secondary Antibodies 
Target Host Conjugate Manufacturer Product #  Concentration 
mouse IgG goat HRP Sigma-Aldrich A9917  1:5000-10000 
mouse IgG goat Alexa Fluor 594 
Life 
Technologies A11005  1:1000 
chicken IgG Goat Alexa Fluor 488 
Life 
Technologies A11039  1:1000 
ChIP Antibodies 
Target Host Epitope Manufacturer Product # IsoType Concentration 
H3K9me1 mouse 1-18 Millipore 17-680 IgG 2 µl/IP 
H3K9me2 mouse 1-18 Millipore 17-681 IgG 4 µl/IP 
H3K9Ac rabbit polyclonal Millipore 17-658 IgG 3 µg/IP 
H4K20me1 rabbit 15-24 Millipore 17-651 IgG 4 µg/IP 
H4K8Ac rabbit polyclonal Millipore 17-10099 IgG 1.5 µl/IP 
H4K20me3 rabbit 18-22 Millipore 17-671 IgG 7 µl/IP 




Supplementary Table 9 | Viral transduction and light stimulation parameters for in vivo 
LITE-mediated activation of Grm2 in the mouse infralimbic cortex (ILC). Grm2 mRNA 
levels in the ipsilateral LITE-expressing hemisphere are compared with the contralateral 




Supplementary Table 10 | qPCR primers used for CHIP-qPCR 
target Primers 
Grm2 promoter Forward: CTGTGCTGAAGGATCTGGGG 
Reverse: ATGCTGCAGGCATAGGACAA 




Cell Signaling Technologies SimpleChIP® Mouse MYT-1 
Promoter Primers #8985 





ILC Hemisphere (ipsilateral) ILC Hemisphere 
(contralateral) 
 AAV vector Light 
stimulation 
AAV vector 
GFP GFP yes mCherry 
LITEs / no Light TALE-CIB1::CRY2PHR-
VP64 
no mCherry 




Supplementary Table 11 | sgRNA guide sequences 
sgRNA ID Guide sequence Gene Organism 
sgRNA0001 TGGTTCAGTGGCTGCGTGTC Neurog2 Mus musculus 
sgRNA0002 TGTTTTCTTGGTGGTATATA Neurog2 Mus musculus 
sgRNA0003 ATACGATGAAAAGAATAAGC Neurog2 Mus musculus 
sgRNA0004 GGGGGAGAGGGACTAAAGAA Neurog2 Mus musculus 
sgRNA0005 GGGCGGGGGAAGGGTAGGTG Neurog2 Mus musculus 
sgRNA0006 ATTAGATAAAGGGGGGACGG Neurog2 Mus musculus 
sgRNA0007 CGGCTTTAACTGGAGTGCCT Neurog2 Mus musculus 
sgRNA0008 GAGCAGCGTCTTCGAGAGTG VEGFA Homo sapiens 
sgRNA0009 GGTGAGTGAGTGTGTGCGTG VEGFA Homo sapiens 
sgRNA0010 GCGCGGCGCGGAAGGGGTTA NTF3 Homo sapiens 
sgRNA0011 GCGGCGCGGCGCGGGCCGGC NTF3 Homo sapiens 
sgRNA0012 GCAGCCGCTCGCTGCAGCAG ASCL1 Homo sapiens 
sgRNA0013 ATGGAGAGTTTGCAAGGAGC ASCL1 Homo sapiens 
sgRNA0014 GGGCCCCTGCGGCCACCCCG MYOD1 Homo sapiens 
sgRNA0015 GAGGTTTGGAAAGGGCGTGC MYOD1 Homo sapiens 
sgRNA0021 TTGTACTCTCTGAGGTGCTC IL1RN Homo sapiens 
sgRNA0022 TACGCAGATAAGAACCAGTT IL1RN Homo sapiens 
sgRNA0023 GCATCAAGTCAGCCATCAGC IL1RN Homo sapiens 
sgRNA0024 TGAGTCACCCTCCTGGAAAC IL1RN Homo sapiens 
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MS2 activator sequences 
In all sgRNA backbone sequences, NNNNNNNNNNNNNNNNNNNN represents the locus-specific guide 
sequence of each sgRNA. 
 




































Description: The MS2-VP64 activator protein consists of the following domains from N-term to C-term: 
the N55K mutant of the MS2 bacteriophage coat protein 3X GGGGS linker, SV40 nuclear localization 
signal, and VP64 activation domain. Functionally, the MS2 domain binds to its specific RNA aptamer, the 
3XGGGGS linker provides mechanical flexibility between the MS2 and VP64 domains, the SV40 nuclear 
localization signal facilitates transport of the protein into the nucleus, and the VP64 activation domain 
promotes transcriptional activation. 
 





Description: +83 nucleotide chimeric backbone used in Zhang Lab CRISPR/Cas9 publications 
 





Description: MS2-binding loop ggccAACATGAGGATCACCCATGTCTGCAGggcc replaces nucleotides 
+13 to +16 and nucleotides +53 to +56 of the standard sgRNA backbone. The resulting structure is an 
sgRNA scaffold in which the tetraloop and stemloop 2 sequences have been replaced by an MS2 binding 
loop. The tetraloop and stemloop 2 were selected for replacement based on information obtained from the 
Cas9/RNA/DNA crystal structure. Specifically, the tetraloop and stemloop 2 were found to protrude from 
the Cas9 protein in such a way which suggested that adding an MS2 binding loop would not interfere with 
any Cas9 residues. Additionally, the proximity of the tetraloop and stemloop 2 sites to the DNA suggested 
that localization to these locations would result in a high degree of interaction between the DNA and any 
recruited protein, such as a transcriptional activator. 
 




Description: The MS2-binding loop sequence ggccAACATGAGGATCACCCATGTCTGCAGggcc 
replaces nucleotides +13 to +16 of the standard sgRNA backbone. The sequence CGCC replaces 
nucleotides +49 to +52 of the standard sgRNA backbone. The sequence GGCG replaces nucleotides +57 to 
+60 of the standard sgRNA backbone. The tetraloop MS2-binding loop insertion was designed with the 
same rationale as described for pSAMca009 above. The CGCC and GGCG sequences replace the stem 
portion of stemloop 2. The increased base-pairing strength of the CGCC-GGCG stem compared to the 
original ACTT-AAGT stem was hypothesized to provide additional stability to the stemloop 2 structure, 
thereby increasing sgRNA performance or longevity. 
 




























Description: The MS2-p65 activator protein consists of the following domains from N-term to C-term: the 
N55K mutant of the MS2 bacteriophage coat, 3X GGGGS linker, SV40 nuclear localization signal, and 
p65 activation domain. Functionally, the MS2 domain binds to its specific RNA aptamer, the 3XGGGGS 
linker provides mechanical flexibility between the MS2 and p65 domains, the SV40 nuclear localization 
signal facilitates transport of the protein into the nucleus, and the p65 activation domain promotes 
transcriptional activation. 
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